A Study of Renal Autologous Cell Therapy (REACT®) in Type 2 Diabetics With Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02836574

Recruitment Status : Active, not recruiting

First Posted : July 19, 2016

Last Update Posted : February 15, 2022

Sponsor:

Collaborator:

CTI Clinical Trial and Consulting Services

Information provided by (Responsible Party):

Prokidney

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	May 2025
Estimated Study Completion Date :	May 2028

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Stavas J, Gerber D, Coca SG, Silva AL, Johns A, Jain D, Bertram T, Díaz-González de Ferris M, Bakris G. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022;53(1):50-58. doi: 10.1159/000520231. Epub 2022 Jan 14.

To Top